These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 11950621)

  • 41. Neonatal oxygen exposure in rats leads to cardiovascular and renal alterations in adulthood.
    Yzydorczyk C; Comte B; Cambonie G; Lavoie JC; Germain N; Ting Shun Y; Wolff J; Deschepper C; Touyz RM; Lelièvre-Pegorier M; Nuyt AM
    Hypertension; 2008 Nov; 52(5):889-95. PubMed ID: 18852387
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Benazepril, an angiotensin-converting enzyme inhibitor, alleviates renal injury in spontaneously hypertensive rats by inhibiting advanced glycation end-product-mediated pathways.
    Liu XP; Pang YJ; Zhu WW; Zhao TT; Zheng M; Wang YB; Sun ZJ; Sun SJ
    Clin Exp Pharmacol Physiol; 2009 Mar; 36(3):287-96. PubMed ID: 19018797
    [TBL] [Abstract][Full Text] [Related]  

  • 43. What should we advise our patients about taking antioxidants?
    Pickering TG
    J Clin Hypertens (Greenwich); 2003; 5(3):231-3. PubMed ID: 12826791
    [No Abstract]   [Full Text] [Related]  

  • 44. The complex role of PPARgamma in renal dysfunction in obesity: managing a Janus-faced receptor.
    Dobrian AD
    Vascul Pharmacol; 2006 Jul; 45(1):36-45. PubMed ID: 16716756
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: a post hoc analysis from the RENAAL study and the Irbesartan Diabetic Nephropathy Trial.
    McMullan CJ; Lambers Heerspink HJ; Parving HH; Dwyer JP; Forman JP; de Zeeuw D
    Am J Kidney Dis; 2014 Nov; 64(5):714-22. PubMed ID: 25064674
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Oxidants in chronic kidney disease.
    Shah SV; Baliga R; Rajapurkar M; Fonseca VA
    J Am Soc Nephrol; 2007 Jan; 18(1):16-28. PubMed ID: 17167116
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Role of reactive oxygen species in the pathogenesis of diabetic nephropathy.
    Ha H; Hwang IA; Park JH; Lee HB
    Diabetes Res Clin Pract; 2008 Nov; 82 Suppl 1():S42-5. PubMed ID: 18845352
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Reactive oxygen species and vascular remodelling in hypertension: still alive.
    Xu S; Touyz RM
    Can J Cardiol; 2006 Sep; 22(11):947-51. PubMed ID: 16971980
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antioxidant effect of carnosine treatment on renal oxidative stress in streptozotocin-induced diabetic rats.
    Yay A; Akkuş D; Yapıslar H; Balcıoglu E; Sonmez MF; Ozdamar S
    Biotech Histochem; 2014 Nov; 89(8):552-7. PubMed ID: 24834928
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Taurine ameliorates alloxan-induced diabetic renal injury, oxidative stress-related signaling pathways and apoptosis in rats.
    Das J; Sil PC
    Amino Acids; 2012 Oct; 43(4):1509-23. PubMed ID: 22302365
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Endogenous Ouabain: Recent Advances and Controversies.
    Hamlyn JM; Blaustein MP
    Hypertension; 2016 Sep; 68(3):526-32. PubMed ID: 27456525
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Renal and stroke protection in hypertensive patients at CV risk.
    Cardiovasc J Afr; 2007; 18(5):337, 340. PubMed ID: 17985036
    [No Abstract]   [Full Text] [Related]  

  • 53. Oxygen free radicals and the penis.
    Jones RW; Rees RW; Minhas S; Ralph D; Persad RA; Jeremy JY
    Expert Opin Pharmacother; 2002 Jul; 3(7):889-97. PubMed ID: 12083989
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Blood pressure in Navajo Indians and its association with type 2 diabetes and renal and cardiovascular disease.
    Hoy W; Light A; Megill D
    Am J Hypertens; 1994 Apr; 7(4 Pt 1):321-8. PubMed ID: 8031547
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Endothelial dysfunction: the common consequence in diabetes and hypertension.
    Wong WT; Wong SL; Tian XY; Huang Y
    J Cardiovasc Pharmacol; 2010 Apr; 55(4):300-7. PubMed ID: 20422734
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Are peroxisome proliferator-activated receptors new therapeutic targets in diabetic and non-diabetic nephropathies?
    Boulanger H; Mansouri R; Gautier JF; Glotz D
    Nephrol Dial Transplant; 2006 Oct; 21(10):2696-702. PubMed ID: 16880183
    [No Abstract]   [Full Text] [Related]  

  • 57. Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy.
    Elmarakby AA; Sullivan JC
    Cardiovasc Ther; 2012 Feb; 30(1):49-59. PubMed ID: 20718759
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Glomerular filtration rate and cardiovascular risk: prognostic and therapeutic implications].
    Ratto E; Leoncini G; Viazzi F; Pontremoli R
    G Ital Nefrol; 2008; 25(1):21-31. PubMed ID: 18264915
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Angiotensin converting enzyme inhibitors: the end of end-stage renal disease?
    Feig PU; Rutan GH
    Ann Intern Med; 1989 Sep; 111(6):451-3. PubMed ID: 2672924
    [No Abstract]   [Full Text] [Related]  

  • 60. Oxygen radicals and renal diseases.
    Klahr S
    Miner Electrolyte Metab; 1997; 23(3-6):140-3. PubMed ID: 9387104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.